Loading...
•
Jun 28
Bioventus Q2 2025 Earnings Report
Bioventus reported its second quarter financial results, with a slight revenue decline but significant improvements in net income and non-GAAP EPS.
Key Takeaways
Bioventus delivered a strong second quarter, with reported revenue of $147.7 million, a 2.4% decline year-over-year due to a prior-year divestiture. However, organic revenue grew by 6.2%, driven by double-digit organic growth in Surgical Solutions and Restorative Therapies. The company significantly improved its net income to $7.5 million from a loss of $25.7 million in the prior year, and non-GAAP EPS increased by 31% to $0.21. Cash from operations also saw a substantial increase of 71% to $25.9 million.
Reported revenue for Q2 2025 was $147.7 million, a 2.4% decrease year-over-year, primarily due to the divestiture of the Advanced Rehabilitation Business.
Organic revenue grew by 6.2%, with strong performance in Surgical Solutions and Restorative Therapies.
Net income attributable to Bioventus Inc. improved significantly to $7.5 million, compared to a net loss of $25.7 million in the prior-year period.
Non-GAAP diluted earnings per share increased by 31% to $0.21, driven by lower interest expense and equity-based compensation.
Bioventus
Bioventus
Bioventus Revenue by Segment
Bioventus Revenue by Geographic Location
Revenue by Segment
Pain Treatments Revenue
CapyFin.comSurgical Solutions Revenue
CapyFin.comRestorative Therapies Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Bioventus reiterated its full-year 2025 financial guidance, expecting net sales between $560 million and $570 million, Adjusted EBITDA between $112 million and $116 million, and Non-GAAP EPS between $0.64 and $0.68.
Positive Outlook
- Reiterated net sales guidance of $560 million to $570 million for full year 2025.
- Expected organic growth of approximately 6.1% to 8.0% for full year 2025, even with the impact of the Advanced Rehabilitation Business divestiture.
- Reiterated Adjusted EBITDA guidance of $112 million to $116 million for full year 2025.
- Anticipated 100 basis points in Adjusted EBITDA Margin growth compared to 2024.
- Reiterated Non-GAAP EPS guidance of $0.64 to $0.68, reflecting an increase of 30.6% to 38.8%.
Challenges Ahead
- Guidance assumes successful offset of $5 million related to foreign exchange expense incurred in the first half of the year.
- Guidance assumes successful offset of the full year expected impact of current tariffs.
- Guidance does not assume additional impact from U.S. dollar fluctuation in the second half of the year.
- The company does not provide U.S. GAAP financial measures on a forward-looking basis due to uncertainties in predicting acquisition/divestiture expenses and fair-value adjustments.
- Future results could be materially different from GAAP due to unpredictable items.
Revenue & Expenses
Visualization of income flow from segment revenue to net income